About Breath Therapeutics
Breath Therapeutics is a company based in Munchen (Germany) founded in 2016 was acquired by Zambon Pharma in July 2019.. Breath Therapeutics has raised $46.01 million across 1 funding round from investors including Gimv, Zambon Pharma and Gilde Healthcare. Breath Therapeutics offers products and services including Liposomal Cyclosporine A, Active Pharmaceutical Ingredients, and Zcube Solutions. Breath Therapeutics operates in a competitive market with competitors including GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
- Headquarter Munchen, Germany
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Zambon Company S.P.A.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$46.01 M (USD)
in 1 rounds
-
Latest Funding Round
$46.01 M (USD), Series A
Mar 08, 2017
-
Investors
Gimv
& 3 more
-
Employee Count
Employee Count
-
Acquired by
Zambon Pharma
(Jul 25, 2019)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Breath Therapeutics
Breath Therapeutics offers a comprehensive portfolio of products and services, including Liposomal Cyclosporine A, Active Pharmaceutical Ingredients, and Zcube Solutions. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Inhalation therapy for Bronchiolitis Obliterans Syndrome patients
Develops intermediates for pharmaceutical industry applications
Identifies digital therapies to improve patient care outcomes
Funding Insights of Breath Therapeutics
Breath Therapeutics has successfully raised a total of $46.01M through 1 strategic funding round. The most recent funding activity was a Series A round of $46.01 million completed in March 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Series A — $46.0M
-
First Round
First Round
(08 Mar 2017)
- Investors Count 3
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2017 | Amount | Series A - Breath Therapeutics | Valuation | Gimv , Sofinnova Partners |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Breath Therapeutics
Breath Therapeutics has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Gimv, Zambon Pharma and Gilde Healthcare. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity firm
|
Founded Year | Domain | Location | |
|
Private equity and venture captial firm focused on healthcare sectors
|
Founded Year | Domain | Location | |
|
Sofinnova Partners is focused on life sciences and healthcare investments.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Breath Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Breath Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Breath Therapeutics Comparisons
Competitors of Breath Therapeutics
Breath Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of pharmaceuticals and vaccines for various therapeutic areas
|
|
| domain | founded_year | HQ Location |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| domain | founded_year | HQ Location |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| domain | founded_year | HQ Location |
Yeast cells are genetically engineered to produce medicinal products.
|
|
| domain | founded_year | HQ Location |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| domain | founded_year | HQ Location |
CRISPR-engineered cell and gene therapies are developed for research applications.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Breath Therapeutics
Frequently Asked Questions about Breath Therapeutics
When was Breath Therapeutics founded?
Breath Therapeutics was founded in 2016 and raised its 1st funding round 1 year after it was founded.
Where is Breath Therapeutics located?
Breath Therapeutics is headquartered in Munchen, Germany. It is registered at Munchen, Bayern, Germany.
Is Breath Therapeutics a funded company?
Breath Therapeutics is a funded company, having raised a total of $46.01M across 1 funding round to date. The company's 1st funding round was a Series A of $46.01M, raised on Mar 08, 2017.
What does Breath Therapeutics do?
Breath Therapeutics, a spin-off of PARI Pharma, is developing inhalation therapies for delivering drugs for treating severe respiratory orphan diseases. The company is using proprietary drug formulations optimized for inhaled administration with exclusively licensed, high-performance nebulizers. Its lead product is a drug-device innovation for inhalation therapy to treat Bronchiolitis Obliterans Syndrome (BOS) in patients after lung transplantation. The companys inhalation therapy involves a formulation of liposomal cyclosporine A for inhalation and an optimized eFlow technology nebulizer enabling remote adherence monitoring. The company has completed phase 2 trials preparing to initiate two robust Phase 3 clinical trials in the US and Europe.
Who are the top competitors of Breath Therapeutics?
Breath Therapeutics's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
What products or services does Breath Therapeutics offer?
Breath Therapeutics offers Liposomal Cyclosporine A, Active Pharmaceutical Ingredients, and Zcube Solutions.
Who are Breath Therapeutics's investors?
Breath Therapeutics has 4 investors. Key investors include Gimv, Zambon Pharma, Gilde Healthcare, and Sofinnova Partners.